Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hospital Universitario Central de Asturias | OTHER |
| National Research Council, Spain | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this pilot study is to evaluate whether a probiotic supplement improves gastrointestinal (GI) function.
Sixty volunteers with functional GI disorders (Functional dyspepsia according to Rome-III criteria) will be recruited for a randomised, double-blind, placebo-controlled, two-arm parallel study in which the effect upon the gastrointestinal function of a probiotic mix containing bifidobacteria and lactobacilli (manufactured by Biopolis SL) will be compared with placebo (maltodextrin). The study design includes a 4 week run-in period, in which the volunteers will not consume any probiotics/prebiotics, followed by a 4 weeks intervention period (a daily capsule of placebo or probiotic) and an 8 weeks washout period. At the beginning/end of each period questionnaires in gastrointestinal function, dyspepsia related symptoms and diet will be carried out. A serum sample will be taken for cytokine levels determination. A faecal sample will be taken for 16S microbial population profiling and for determining the faecal levels of Bifidobacterium, Bacteriodes, Faecalibacterium, Akkermansia, Lactobacillus and Blautia by qPCR and the concentration of the main bacterial metabolites; acetate, propionate and butyrate by gas-chromatography.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Test product | Active Comparator | The volunteers, that have been randomly assigned to the Test product arm of the study, will be administered one oral capsule/day of the Probiotic mix CBP-004019/C (Biopolis SL) during the intervention period (1 month). The product contains 1X10Exp9 cfu/capsule of the probiotic mix (Bifidobacterium lactis, Bifidobacterium longum, Lactobacilus casei and Lactobacillus rhamnosus) plus maltodextrin and sugar. |
|
| Placebo product | Placebo Comparator | The volunteers that have been randomly assigned to this arm of the study will receive one oral capsule per day of the placebo product (Biopolis SL) during the 1 month intervention period. The product contains maltodextrin and sugar. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Probiotic mix CBP-004019/C | Dietary Supplement | One capsule per day of the probiotic mix CBP-004019/C during one month. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Functional dyspepsia symptoms | Physician determined symptoms according to Rome III criteria. | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Relative proportions of the main microbial groups of the intestinal microbiota | Global profile of intestinal microbiota composition established by 16S rRNA profiling | 3 months |
| Dyspepsia associated quality of life |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Empar Chenol, PhD | Contact | +34963160299 | empar.chenoll@biopolis.es | |
| Salvador Genoves, PhD | Contact | +34963160299 | salvador.genoves@biopolis.es |
| Name | Affiliation | Role |
|---|---|---|
| Adolfo Suárez, MD, PhD | Hospital Universitario Central de Asturias, Servicio de Gastroenterología | Principal Investigator |
| Miguel Gueimonde, PhD | Consejo Superior de Investigaciones Científicas, IPLA-CSIC | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Universitario Central de Asturias | Recruiting | Oviedo | Principality of Asturias | 33011 | Spain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012817 | Signs and Symptoms, Digestive |
| D004415 | Dyspepsia |
| D015746 | Abdominal Pain |
| D005414 | Flatulence |
| ID | Term |
|---|---|
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Dietary Supplement | One capsule per day of the placebo (maltodextrin) during one month. |
|
Questionaires for symptoms and QoL associated to dyspepsia and for anxiety/depression
| 3 months |
| Serum IFN-gamma levels | Determination of the serum concentration (pg/mL) of IFN-gamma | 3 months |
| Serum TNF-alpha levels | Determination of the serum concentration (pg/mL) of TNF-alpha | 3 months |
| Serum IL-12 levels | Determination of the serum concentration (pg/mL) of IL-12 | 3 months |
| Serum IL-4 levels | Determination of the serum concentration (pg/mL) of IL-4 | 3 months |
| Serum IL-10 levels | Determination of the serum concentration (pg/mL) of IL-10 | 3 months |
| Serum TGF-beta levels | Determination of the serum concentration (pg/mL) of TGF-beta | 3 months |
| Fecal levels of Bifidobacterium | Determination of the levels (log cells/gr) of Bifidobacterium in fecal samples by qPCR | 3 months |
| Fecal levels of Lactobacillus | Determination of the levels (log cells/gr) of Lactobacillus in fecal samples by qPCR | 3 months |
| Fecal levels of Bacteroides | Determination of the levels (log cells/gr) of Bacteroides in fecal samples by qPCR | 3 months |
| Fecal levels of Blautia | Determination of the levels (log cells/gr) of Blautia in fecal samples by qPCR | 3 months |
| Fecal levels of Akkermansia | Determination of the levels (log cells/gr) of Akkermansia in fecal samples by qPCR | 3 months |
| Fecal levels of Faecalibacterium | Determination of the levels (log cells/gr) of Faecalibacterium in fecal samples by qPCR | 3 months |